Phaseline

Targets › PPARA

PPARA (Peroxisome proliferator-activated receptor alpha): drug programs, companies and trials

11 programs from 10 companies in 30 trials: 15 Phase 3, 10 Phase 2, 3 Phase 1, 2 Phase 4; Gastroenterology, Metabolic and endocrine, Oncology; next expected readout Dec 2026.

Ligand-activated transcription factor. Key regulator of lipid metabolism. (UniProt, Q07869)

Open in Phaseline: the race on PPARA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kowa CompanyPemafibrate
Peroxisome proliferator-activated receptor alpha agonist
PPARAPhase 4HypercholesterolemiaJul 2027
IpsenElafibranor
Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor delta agonist
PPARA, PPARDPhase 3Primary Biliary Cholangitis; Primary Biliary Cirrhosis; Primary Biliary Cholangitis (PBC); Primary Sclerosing CholangitisDec 2026
Zydus TherapeuticsSaroglitazar
Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist
PPARA, PPARGPhase 3Primary Biliary Cholangitis; Hepatic Impairment; Cholestatic Liver DiseaseDec 2026
Xijing Hospital of Digestive DiseasesFenofibrate
Peroxisome proliferator-activated receptor alpha agonist
PPARAPhase 3Primary Biliary Cholangitis; Primary Biliary Cirrhosis; Primary Biliary Cholangitis (PBC)Apr 2027
Inventiva PharmaLanifibranor (IVA337)
Peroxisome proliferator-activated receptor agonist
PPARG, PPARA, PPARDPhase 3NASH - Nonalcoholic SteatohepatitisSep 2027
Assistance Publique - Hôpitaux de ParisBezafibrate
Peroxisome proliferator-activated receptor agonist
PPARG, PPARA, PPARDPhase 3BPCDec 2027
The First Affiliated Hospital of Xiamen UniversityChiglitazar
Peroxisome proliferator-activated receptor agonist
PPARG, PPARA, PPARDPhase 2Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid LeukemiaDec 2026
RDC ClinicalOleoylethanolamide (Trpti)
Endocannabinoid-like compound; TRPV1 and PPAR-alpha agonist with appetite regulation and s
TRPV1, PPARAPhase 2Sleep Disorder (Disorder); Healthy VolunteersFeb 2027
RDC ClinicalPalmitoylethanolamide (PEA)
Endocannabinoid-like lipid signaling molecule; acts as agonist at TRPV1 and PPARα receptor
TRPV1, PPARAPhase 2Sleep Disorder (Disorder); Healthy; Persistent Postural Perceptual DizzinessFeb 2027
Medical University of ViennaFenofibric acid
Peroxisome proliferator-activated receptor alpha agonist
PPARAPhase 2Medulloblastoma RecurrentApr 2030
Shanghai Jiao Tong University School of MedicineChiglitazar
Peroxisome proliferator-activated receptor agonist
PPARG, PPARA, PPARDPhase 2MASH - Metabolic Dysfunction-Associated SteatohepatitisDec 2030

Conditions

Primary Biliary Cholangitis (7) Primary Biliary Cholangitis (PBC) (4) Primary Biliary Cirrhosis (2) Primary Sclerosing Cholangitis (2) BPC (2) Sleep Disorder (Disorder) (2) Hypercholesterolemia (1) Hepatic Impairment (1) Cholestatic Liver Disease (1) Medulloblastoma Recurrent (1) MASH - Metabolic Dysfunction-Associated Steatohepatitis (1) Relapsed or Refractory Acute Myeloid Leukemia (1)

Modalities

small molecule (8), mixed (1)

Companies

RDC Clinical (2) Ipsen (1) Xijing Hospital of Digestive Diseases (1) Assistance Publique - Hôpitaux de Paris (1) Kowa Company (1) Zydus Therapeutics (1) Medical University of Vienna (1) Shanghai Jiao Tong University School of Medicine (1) The First Affiliated Hospital of Xiamen University (1) Inventiva Pharma (1)

Related targets

PPARD (5) PPARG (5) TRPV1 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.